Malone Margaret, Alger-Mayer Sharon A
Department of Pharmacy Practice, Albany College of Pharmacy, Albany, NY 12208, USA.
Ann Pharmacother. 2003 Nov;37(11):1598-602. doi: 10.1345/aph.1D183.
Pharmacists, especially those in community practice, should increase their level of intervention in dealing with the nationwide epidemic of obesity since they interact with large numbers of the public on a regular basis. We hypothesized that patients who receive medication for weight loss may have an improved therapeutic outcome if they received additional support from their community pharmacist.
To evaluate the impact of pharmacist support on patient persistence with orlistat.
Pharmacists were trained in basic obesity management skills. Patients who were prescribed orlistat and attending an outpatient nutrition program were invited to participate in the study. All patients agreed to receive pharmaceutical care. Those who lived where the service was available were assigned to the intervention (I) group and those who did not were assigned to the control (C) group. All patients received usual care provided by the outpatient clinic.
Thirty patients, 15 in the I group and 15 in the C group, were recruited. Both groups were predominantly women (87%) with a mean +/- SD age of 43.8 +/- 9.7 years. Patients in the I group had significantly greater persistence with orlistat therapy as assessed by duration of therapy (p = 0.006) and number of patients completing the 26-week study (7 I, 2 C; p = 0.046). There was no significant difference in percent of weight loss between groups (p > 0.05).
In this pilot study, patients receiving pharmaceutical care took orlistat longer than the controls and had improved outcome with orlistat therapy.
药剂师,尤其是社区药剂师,应提高其在应对全国性肥胖流行问题上的干预水平,因为他们经常与大量公众互动。我们假设,接受减肥药物治疗的患者如果能从社区药剂师那里获得额外支持,可能会有更好的治疗效果。
评估药剂师支持对患者使用奥利司他依从性的影响。
对药剂师进行基本肥胖管理技能培训。邀请那些被开了奥利司他并参加门诊营养项目的患者参与研究。所有患者均同意接受药学服务。居住在有该服务地区的患者被分配到干预(I)组,那些不住在该地区的患者被分配到对照(C)组。所有患者均接受门诊诊所提供的常规护理。
招募了30名患者,I组15名,C组15名。两组主要为女性(87%),平均年龄±标准差为43.8±9.7岁。根据治疗持续时间(p = 0.006)和完成26周研究的患者数量(I组7名,C组2名;p = 0.046)评估,I组患者对奥利司他治疗的依从性显著更高。两组间体重减轻百分比无显著差异(p > 0.05)。
在这项初步研究中,接受药学服务的患者服用奥利司他的时间比对照组更长,且奥利司他治疗效果更好。